

Europe Pneumococcal Vaccine Market Set to Boom Anticipating Explosive 5.7% CAGR Growth, Surpass \$2.9 Billion by 2032

The growing existence of pneumonia fuels the demand for the European pneumococcal vaccine market.

NEW YORK CITY, NY, UNITED STATES, November 20, 2024 /EINPresswire.com/ -- The Europe pneumococcal vaccine market report assesses the competitive scenario of the market, examining all the established players and new market entrants.



Government and health firms are carrying out robust vaccination programs and public health crusades to encourage pneumococcal vaccination."

Polaris Market Research

The Europe pneumococcal vaccine market is projected to reach a value of \$2.9 billion by 2032, growing at a CAGR of 5.7% from 2024 to 2032. The market is driven by the increasing prevalence of pneumonia and the growing awareness of the benefits of pneumococcal vaccination. The market is also expected to be driven by the increasing number of people aged 65 and above, who are more susceptible to pneumonia. The market is also expected to be driven by the increasing number of people aged 2 and 18 years old, who are also susceptible to pneumonia. The market is also expected to be driven by the increasing number of people aged 2 and 18 years old, who are also susceptible to pneumonia.

There are two kinds of vaccines for pneumonia that safeguard against varied kinds of contamination. Pneumococcal conjugate vaccines (PCVs) involve PCV 15, PCV 20, and PCV 21. The aggregate in the name notifies how many kinds of bacteria the vaccine safeguards against. The Pneumococcal polysaccharide vaccine (PPSV23) safeguards against 23 kinds of pneumonia bacteria.

Children below 5 years old, adults crossing the age of 65, and other children and grownups with a probability of pneumonia should acquire a PCV vaccine. Doctors may offer children with specific conditions who are between 2 and 18 years old the PPSV23 vaccine. As per the published report, Europe registers 230,000 deaths each year generated by pneumonia. Governments and health firms in the region are applying robust vaccination programs as a prohibitive estimate against pneumonia, impacting the Europe pneumococcal vaccine market demand favourably.

Children below 5 years old, adults crossing the age of 65, and other children and grownups with a probability of pneumonia should acquire a PCV vaccine. Doctors may offer children with specific conditions who are between 2 and 18 years old the PPSV23 vaccine. As per the published report, Europe registers 230,000 deaths each year generated by pneumonia. Governments and health firms in the region are applying robust vaccination programs as a prohibitive estimate against pneumonia, impacting the Europe pneumococcal vaccine market demand favourably.

For more information, visit <https://www.polarismarketresearch.com/industry-analysis/europe-pneumococcal-vaccine->

<https://www.polarismarketresearch.com/industry-analysis/europe-pneumococcal-vaccine->

[market/request-for-sample](#)

□□□ □□□□□□ □□□□□□□□□□

- The Europe pneumococcal vaccine market size was valued at USD 1.8 billion in 2023 and is projected to grow to USD 2.9 billion by 2032.
- The escalating R&D for advancing new vaccines fuels the need for pneumococcal vaccine in Europe.
- The market segmentation is primarily based on type, product, end user, and country.
- The study provides market insights into Germany, France, the UK, Italy, Spain, Netherlands, Russia, and the rest of Europe.



□□□□□□□□□□ □□□□□□□□□□

□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□ □□ □□□□□□□□□□□□□□□□. □□□ □□□ □□□□□□ □□□□□□□□□□ □□□□ □□:

- Astellas Pharma Inc
- CSL Ltd
- GSK plc
- Merck & Co. Inc
- Panacea Biotech Ltd
- GPN Vaccines
- SK Bioscience
- Pfizer Inc.
- Sanofi S.A
- Serum Life Sciences Ltd
- Talley Group Ltd
- Walvax Biotechnology Co. Ltd

□□□□□□□□□□ □□ □□□□□□□□ □□□□□□□□□□□□ □□ □□□□□□ □□□□□□□□ □□□□□□. □□□□, □□□□ □□□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□ □□□□□□□□ □□ □□□□ □□□□□□□□□□□□. □□□□ □□□ □□□□ □□ □□□ □□□□□ □□□□□□□□□□□□□□□□□:

- In June 2023, SK Bioscience declared the affirmative outcomes of its phase II clinical trials like with the 21 Valent pneumococcal conjugate vaccine contender GBP410, which was advanced in alliance with Sanofi.
- In November 2023, GPN Vaccines expanded its alliance with BioCina, a contract development and manufacturing firm, to push the making of vaccines for meningitis, pneumonia, and febrile bacteremia.

□□□□□□ □□ □ □□□□□□□ □□ □□□□ □□□□□□ □□□□□□□□:

<https://www.polarismarketresearch.com/industry-analysis/europe-pneumococcal-vaccine-market/request-for-discount-pricing>

□□□□□□ □□□□□□□ □□ □□□□□□□□□□□□□□

Escalating Research & Development: The growing R&D for advancing contemporary vaccines is expected to push the market. Inventions such as conjugate vaccines or amalgamated vaccines that safeguard against manifold pathogens fuel the Europe pneumococcal vaccine market growth.

Collaboration between Public and Private Sectors: The association between the public and private sectors augmenting the vaccine dissemination framework generates an enormous possibility in the market during the forecast period.

Growing Funding in Product Advancement: The growing funding in product advancement, caused a generation of more productive vaccines that earmark a wider gamut of pneumococcal strains.

□□□□□□□□ □□□□□□□□

The UK is anticipated to witness a significant CAGR from 2024 to 2032. The country's robust growth is due to growing cases of pneumonia and meningitis. As per the UK government data, an additional 5,000 invasive pneumococcal illness cases are expected to be recorded on a yearly basis in England.

Germany accounted for the largest share of the Europe pneumococcal vaccine market share. This is primarily because of the region's strong healthcare framework and extensive vaccination programs.

□□□□□□□□□□ □□□□□□□□

By Type Outlook

- Pneumococcal Conjugate Vaccines
- Pneumococcal Polysaccharide Vaccines

By Product Outlook

- Prevnar 13
- Synflorix
- Pneumovax 23
- VAXNEUVANCE
- PNEUMOSIL
- Others

By End User Outlook

- Public Sector
- Private Sector

By Country Outlook

- France
- Germany
- UK
- Italy
- Netherlands
- Spain
- Russia
- Rest of Europe

欲知更多关于欧洲肺炎球菌疫苗市场的情况，请访问：

<https://www.polarismarketresearch.com/industry-analysis/europe-pneumococcal-vaccine-market/inquire-before-buying>

浏览PMR的微型联合供热和发电市场报告覆盖来自不同出版物：

欲知更多关于微型联合供热和发电市场的情况，请访问：<https://www.polarismarketresearch.com/industry-analysis/micro-combined-heat-and-power-market/inquire-before-buying>。2032年，微型联合供热和发电市场将包括：<https://www.polarismarketresearch.com/industry-analysis/micro-combined-heat-and-power-market/inquire-before-buying>、<https://www.polarismarketresearch.com/industry-analysis/micro-combined-heat-and-power-market/inquire-before-buying>、<https://www.polarismarketresearch.com/industry-analysis/micro-combined-heat-and-power-market/inquire-before-buying> & <https://www.polarismarketresearch.com/industry-analysis/micro-combined-heat-and-power-market/inquire-before-buying>。

欲知更多关于T4 DNA连接酶市场的情况，请访问：

T4 DNA Ligase Market

<https://www.polarismarketresearch.com/industry-analysis/t4-dna-ligase-market>

Cell & Gene Therapy Bioanalytical Testing Services Market

<https://www.polarismarketresearch.com/industry-analysis/cell-and-gene-therapy-bioanalytical-testing-services-market>

Plasma Protease C1-inhibitor Market

<https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market>

Surgical Planning Software Market

<https://www.polarismarketresearch.com/industry-analysis/surgical-planning-software-market>

Dental Equipment Market

<https://www.polarismarketresearch.com/industry-analysis/dental-equipment-market>

Polymers, Composites, Nanomaterials & Biomaterials, etc.:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+ +1 929-297-9727

sales@polarismarketresearch.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/762216384>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.